Neptune Wellness Solutions (NEPT)
Echelon Wealth Partners analyst Douglas Loe maintained a Buy rating on Neptune Wellness Solutions on June 30 and set a price target of C$5.00. The company’s shares closed last Thursday at $2.86.
According to TipRanks.com, Loe is a 3-star analyst with an average return of 2.3% and a 46.2% success rate. Loe covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Cipher Pharmaceuticals, and Kalytera Therapeutics.
Currently, the analyst consensus on Neptune Wellness Solutions is a Moderate Buy with an average price target of $4.79.
In a report issued on July 1, Cory Kasimov from J.P. Morgan maintained a Hold rating on Amgen. The company’s shares closed last Thursday at $258.24, close to its 52-week high of $261.46.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 18.6% and a 58.1% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $256.69, implying a 1.5% upside from current levels. In a report issued on June 23, Mizuho Securities also maintained a Hold rating on the stock with a $215.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.